CN102293741B - Bromhexine hydrochlorie injection, its preparation method and application - Google Patents
Bromhexine hydrochlorie injection, its preparation method and application Download PDFInfo
- Publication number
- CN102293741B CN102293741B CN 201110246847 CN201110246847A CN102293741B CN 102293741 B CN102293741 B CN 102293741B CN 201110246847 CN201110246847 CN 201110246847 CN 201110246847 A CN201110246847 A CN 201110246847A CN 102293741 B CN102293741 B CN 102293741B
- Authority
- CN
- China
- Prior art keywords
- bisolvon
- injection
- preparation
- glucose
- aqueous solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002347 injection Methods 0.000 title claims abstract description 43
- 239000007924 injection Substances 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title claims abstract description 43
- 229960003870 bromhexine Drugs 0.000 title claims abstract description 8
- OJGDCBLYJGHCIH-UHFFFAOYSA-N bromhexine Chemical compound C1CCCCC1N(C)CC1=CC(Br)=CC(Br)=C1N OJGDCBLYJGHCIH-UHFFFAOYSA-N 0.000 title claims abstract description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 title abstract 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 48
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 42
- 239000008103 glucose Substances 0.000 claims abstract description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 33
- 238000000034 method Methods 0.000 claims abstract description 28
- 230000008569 process Effects 0.000 claims abstract description 20
- UCDKONUHZNTQPY-UHFFFAOYSA-N bromhexine hydrochloride Chemical compound Cl.C1CCCCC1N(C)CC1=CC(Br)=CC(Br)=C1N UCDKONUHZNTQPY-UHFFFAOYSA-N 0.000 claims description 100
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 20
- 239000008215 water for injection Substances 0.000 claims description 16
- 239000007864 aqueous solution Substances 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 13
- 229910052799 carbon Inorganic materials 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 10
- 239000003172 expectorant agent Substances 0.000 claims description 7
- 230000003419 expectorant effect Effects 0.000 claims description 7
- YENKYLWBLTUEQL-UHFFFAOYSA-N 2-bromohexanoic acid hydrochloride Chemical compound BrC(C(=O)O)CCCC.Cl YENKYLWBLTUEQL-UHFFFAOYSA-N 0.000 claims description 6
- 238000005262 decarbonization Methods 0.000 claims description 5
- 238000012856 packing Methods 0.000 claims description 5
- 238000010521 absorption reaction Methods 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 4
- 239000012982 microporous membrane Substances 0.000 claims description 4
- 238000001179 sorption measurement Methods 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 238000001802 infusion Methods 0.000 claims description 2
- 239000000243 solution Substances 0.000 abstract description 25
- 239000003814 drug Substances 0.000 abstract description 10
- 239000007788 liquid Substances 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 4
- 230000003115 biocidal effect Effects 0.000 abstract description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract description 2
- 230000033228 biological regulation Effects 0.000 abstract description 2
- 206010067484 Adverse reaction Diseases 0.000 abstract 1
- 230000006838 adverse reaction Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 238000009210 therapy by ultrasound Methods 0.000 abstract 1
- 229940090044 injection Drugs 0.000 description 31
- 238000001556 precipitation Methods 0.000 description 13
- 229940093181 glucose injection Drugs 0.000 description 12
- 229960002335 bromhexine hydrochloride Drugs 0.000 description 10
- YRSGDLIATOURQO-UHFFFAOYSA-N ethyl 4-acetyl-5-oxohexanoate Chemical compound CCOC(=O)CCC(C(C)=O)C(C)=O YRSGDLIATOURQO-UHFFFAOYSA-N 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000012360 testing method Methods 0.000 description 7
- 238000005303 weighing Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 5
- 206010001598 Alcohol intolerance Diseases 0.000 description 4
- 206010036790 Productive cough Diseases 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 229960004682 cefoperazone Drugs 0.000 description 2
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 235000005749 Anthriscus sylvestris Nutrition 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 240000004836 Justicia adhatoda Species 0.000 description 1
- YIICVSCAKJMMDJ-UHFFFAOYSA-N L-vasicine Natural products C1=CC=C2N=C3C(O)CCN3CC2=C1 YIICVSCAKJMMDJ-UHFFFAOYSA-N 0.000 description 1
- 208000009481 Laryngeal Edema Diseases 0.000 description 1
- 206010023845 Laryngeal oedema Diseases 0.000 description 1
- XTUVJUMINZSXGF-UHFFFAOYSA-N N-methylcyclohexylamine Chemical compound CNC1CCCCC1 XTUVJUMINZSXGF-UHFFFAOYSA-N 0.000 description 1
- PAMIQIKDUOTOBW-UHFFFAOYSA-N N-methylcyclohexylamine Natural products CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- YIICVSCAKJMMDJ-SNVBAGLBSA-N Peganine Chemical compound C1=CC=C2N=C3[C@H](O)CCN3CC2=C1 YIICVSCAKJMMDJ-SNVBAGLBSA-N 0.000 description 1
- YIICVSCAKJMMDJ-JTQLQIEISA-N Peganine Natural products C1=CC=C2N=C3[C@@H](O)CCN3CC2=C1 YIICVSCAKJMMDJ-JTQLQIEISA-N 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000035286 Spontaneous Remission Diseases 0.000 description 1
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- ADNBOFQFSCPWBA-RJMJUYIDSA-N [Na].O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O Chemical compound [Na].O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O ADNBOFQFSCPWBA-RJMJUYIDSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- -1 biochemistry Substances 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 229960004261 cefotaxime Drugs 0.000 description 1
- GPRBEKHLDVQUJE-VINNURBNSA-N cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 description 1
- 229960000479 ceftriaxone sodium Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229940097572 chloromycetin Drugs 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- FDRNWTJTHBSPMW-GNXCPKRQSA-L disodium;(6r,7r)-7-[[(2e)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-6-oxido-5-oxo-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound [Na+].[Na+].S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)/C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C([O-])=NN1C FDRNWTJTHBSPMW-GNXCPKRQSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- PLHJDBGFXBMTGZ-WEVVVXLNSA-N furazolidone Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)OCC1 PLHJDBGFXBMTGZ-WEVVVXLNSA-N 0.000 description 1
- 229960001625 furazolidone Drugs 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229940066491 mucolytics Drugs 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 1
- 229960003243 phenformin Drugs 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960005053 tinidazole Drugs 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a bromhexine hydrochlorie injection, which contains bromhexine hydrochlorie and glucose and does not contain ethanol. Without ethanol, the injection can be used together with antibiotic drugs and has good stability. In accord with national regulations for pharmaceutical preparations, the injection has stable and reliable quality, and therefore can be used safely. The invention also provides a preparation method of the bromhexine hydrochlorie injection, comprising the steps of: preparing an isotonic water solution of glucose, then predissolving the bromhexine hydrochlorie in the isotonic water solution, and conducting an ultrasonic treatment. According to the method of the invention, the use of ethanol in the process of preparing a liquid preparation of bromhexine hydrochlorie can be avoided successfully, and possible adverse reactions during clinical application are avoided. With a process simple for operation, the method provided in the invention improves the stability of the injection.
Description
Technical field
The invention belongs to the pharmaceutical technology field.Particularly, the present invention relates to a kind of bromhexine hydrochloride injection And its preparation method.
Background technology
Bisolvon (Bromhexine Hydrochloride, (2-amino-3 for N-, the 5-dibromo-benzyl)-and the N-methylcyclohexylamine hydrochlorate) be the hydrochlorate of semisynthetic peganine. derivant, be the effective ingredient in India's expelling phlegm for arresting cough medicine among the people Adhatoda vasica Nees the earliest, 1963 at first synthetic by Keck, the nineteen sixty-five listing.1973 at Discussion on Chinese Listed, for acute and chronic bronchitis, asthma, bronchiectasis, emphysema, especially being applicable to the sticking productive cough of white goes out difficult person and extensively blocks critical emergency case that bronchia causes etc. because of sputum, belong to mucolytic drugs, this medicine can change the viscosity composition of sticking expectorant, reduce the viscosity of expectorant, make expectorant be easy to expectoration.This medicine has become the expectorant of domestic and international clinical first-selection.
Bisolvon is slightly molten in ethanol or chloroform, soluble,very slightly in water, and therefore preparing liquid preparation exists many technical difficulties.The existing method for preparing the Bisolvon liquid preparation mainly uses ethanol to prepare the Bisolvon concentrated solution as solvent, mix with pharmaceutical carrier (sodium chloride, magnesium chloride, lactose sodium, glucose etc.) concentrated solution afterwards, the dilute with water rear decoloring filters, and obtains corresponding Bisolvon liquid preparation.
There is very large defective in application facet at Bisolvon liquid preparation, particularly injection at present, is mainly reflected in the following aspects:
First, Bisolvon is as classical expectorant, often be used for the treatment of clinically respiratory tract disease, even behind surgical operation, also be used for conventional expectoration keeping respiratory smooth, these two kinds of purposes all determined its will inevitably with antibiotic (such as cephalo-type, imidazoles antibiotic) use in conjunction.Yet, find clinically, during the antibiotics medication, contact ethanol or a period of time contact ethanol after drug withdrawal, disulfiram-like reaction appears in patient possibly, show as uncomfortable in chest, breathe hard, laryngeal edema, die Blausucht, dyspnea, increased heart rate, blood pressure drops, limbs fatigue, flush, hyperhidrosis, insomnia, headache, feel sick, vomiting, dim eyesight, drowsiness, hallucination, in a trance even anaphylactic shock occurs, blood pressure drops to 60～70/30～40mmHg, and with loss of consciousness; Even mistaken diagnosis is acute coronary syndrome, heart failure etc.These antibiotics mainly comprise cephalo-type and imdazole derivatives, such as ceftriaxone sodium, cefoperazone, cefotaxime etc.; Metronidazole, tinidazole, ketoconazole, furazolidone, chloromycetin, tolbutamide, glibenclamide, phenformin etc. all can cause disulfiram-like reaction in addition.As the patient during using cefoperazone, drink or drug withdrawal after drink (comprising Chinese liquor, medicated beer, alcopop and confection) in 7 days, oral or intravenous applications contains the medicine of ethanol, perhaps even with ethanol carry out skin degerming or clean cooling, all can produce disulfiram-like reaction, this symptom comes across behind the alcohol exposure 5 to 40 minutes.But although the lighter's spontaneous remission, than severe one even need oxygen uptake and symptomatic treatment.Yet, in the process of preparation Bisolvon concentrated solution, need to use ethanol to be solvent, even but under heated condition, ethanol is also limited to the dissolubility of Bisolvon, therefore in injection, need to introduce a large amount of ethanol, there is larger hazardness in this to patient health so that probably make the patient produce disulfiram-like reaction when Bisolvon injection and antibiotics coupling.
The second, same existence owing to ethanol in the Bisolvon injection, water and ethanol form azeotropic mixture and have reduced sterilising temp in the high temperature sterilize process, and sterilization effect is had a negative impact.
The 3rd, the Bisolvon concentrated solution slightly lets cool, mixes with other carrier concentrated solutions or all may separate out Bisolvon crystallization and crystallization content in the dilute with water process unfixing, causes injection crude drug content unstable behind the decolorization filtering.
Therefore, there is at present the change demand for Bisolvon dissolution process technology, particularly for the demand of the Bisolvon injection that does not contain ethanol.
Summary of the invention
In order to overcome above-mentioned prior art defective, the object of the present invention is to provide a kind of injection of Bisolvon, do not comprise ethanol in this injection.
Another object of the present invention is to provide the preparation method of described Bisolvon injection.
Another purpose of the present invention is to provide the pharmaceutical applications of described Bisolvon injection.
The technical solution used in the present invention is:
On the one hand, the invention provides a kind of Bisolvon injection, the hydrochloric bromhexine of described Bisolvon infusion pump and glucose, and do not comprise ethanol.
Preferably, the concentration of glucose is 50g/L in the described Bisolvon injection; The concentration of Bisolvon is preferably 0.04g/L～0.16g/L in the described Bisolvon injection.
On the other hand, the invention provides the preparation method of described Bisolvon injection, it comprises: then the isotonic aqueous solution of preparation glucose is dissolved in Bisolvon in the described isotonic aqueous solution.
Preferably, bromhexine hydrochloride is dissolved in the described isotonic aqueous solution by supersound process.
Preferably, described preparation method may further comprise the steps:
1) glucose is soluble in water, filter after then adding activated carbon adsorption, filtrate water is diluted to isotonic concentration, thereby obtains the isotonic aqueous solution of glucose; Preferably, described water is water for injection;
2) to through step 1) add Bisolvon in the isotonic aqueous solution that obtains, ultrasonicly make the Bisolvon dissolving, filter after then adding activated carbon adsorption, regulate pH value, filtering with microporous membrane.
According to the specific embodiment of the present invention, described method comprises:
1) the 5000g glucose for injection is dissolved in the 25L water for injection, then adds active carbon 25 to 50g, boil the rear filtering decarbonization of absorption in 30 minutes, then filtrate is diluted to 100L with water for injection, thereby obtains the isotonic aqueous solution of glucose;
2) to through step 1) add 4g～16g Bisolvon in the isotonic aqueous solution that obtains, 30～40 ℃ of lower 25 to 60kHz (preferred 60kHz) made the Bisolvon dissolving in ultrasonic 50 minutes, then add 100g to 400g active carbon (preferably adding the 150g active carbon), filter after stirring absorption in 10 minutes, regulate pH value to 4.0～4.5,0.45 μ m filtering with microporous membrane, packing, sterilization.
Another aspect the invention provides the purposes of described Bisolvon injection in the preparation expectorant.
When preparation Bisolvon liquid preparation, all adopt a large amount of ethanol to dissolve Bisolvon as solvent at present, this has brought very big defective for the use of liquid preparation.Be compared with existing technology, the present invention proposes a kind of new bromhexine hydrochloride injection And its preparation method, it has the following advantages:
The first, the inventor is through the great many of experiments discovery, and glucose has stronger hydrotropy effect to Bisolvon, Bisolvon directly can be dissolved in the isosmotic solution of glucose; And with supersound process, except directly bromhexine hydrochloride being had the very strong hydrotropy effect, more can make the Bisolvon glucose solution be tending towards complete stability.We have proposed a kind of new preparation process of Bisolvon injection accordingly, the method adopts and configures first the glucose isosmotic solution, dissolve again the step of Bisolvon, carry out again supersound process, successfully avoided the use of existing method ethanol in Bisolvon liquid preparation preparation process, improved the stability of injection, and preparation technology is simple to operate;
The second, adopt method of the present invention successfully to prepare the new injection of Bisolvon, this injection does not contain ethanol, experimental results show that said preparation has good stability, and meets national drug preparation regulation, and therefore stable and reliable product quality is used safely, had no side effect.
Therefore, bromhexine hydrochloride injection And its preparation method provided by the invention has overcome the prior art defective, can use clinically safely and effectively, particularly can be safely and the antibiotics coupling, have great application prospect.
The specific embodiment
Below in conjunction with the specific embodiment the present invention is further described in detail, the embodiment that provides is only in order to illustrate the present invention, rather than in order to limit the scope of the invention.
Experimental technique among the following embodiment if no special instructions, is conventional method.Used medicinal raw material, reagent material etc. among the following embodiment if no special instructions, all can be bought and obtain from conventional Chinese medicine, biochemistry, pharmaceutical agent shop.
Embodiment 1 Bisolvon solubility study in water for injection
Precision takes by weighing Bisolvon sample 3g, adds water for injection 1000ml, behind the jolting 20min, have no dissolving, place under the room temperature, respectively at 30min, 60min, 120min, 24h, 48h, 72h under the 1500lx daylight lamp, observe Bisolvon dissolving situation, the result is as follows:
The dissolubility (1) of table 1 Bisolvon in water for injection
+ expression can detect the Bisolvon precipitation
-expression does not detect the Bisolvon precipitation
Precision takes by weighing Bisolvon sample 3g, add water for injection 1000ml, 70 ℃ of heating in water bath (adding reflux condenser), 60 turn/min stirs 30min, and most of dissolving has a small amount of precipitate, place under the room temperature, under the 1500lx daylight lamp, observe Bisolvon dissolving situation respectively at 30min, 60min, 120min, 24h, 48h, 72h, the result is as follows:
The dissolubility (2) of table 2 Bisolvon in water for injection
+ expression can detect the Bisolvon precipitation
-expression does not detect the Bisolvon precipitation
Precision takes by weighing Bisolvon sample 3g, add water for injection 1000ml, 30～40 ℃ of supersound process (25kHz, 100w), be partly dissolved, precipitate is arranged, place under the room temperature, under the 1500lx daylight lamp, observe Bisolvon dissolving situation respectively at 30min, 60min, 120min, 24h, 48h, 72h, the result is as follows:
The dissolubility (3) of table 3 Bisolvon in water for injection
+ expression can detect the Bisolvon precipitation
-expression does not detect the Bisolvon precipitation
Embodiment 2 Bisolvon solubility study in glucose solution
Precision takes by weighing Bisolvon sample 3g, add 5% glucose injection 1000ml, behind the jolting 10min, be partly dissolved, precipitate is arranged, places under the room temperature, respectively at 30min, 60min, 120min, 24h, 48h, 72h under the 1500lx daylight lamp, observe Bisolvon dissolving situation, the result is as follows:
The dissolubility (1) of table 4 Bisolvon in glucose solution
+ expression can detect the Bisolvon precipitation
-expression does not detect the Bisolvon precipitation
Precision takes by weighing Bisolvon sample 3g, adds 5% glucose injection 1000ml, 70 ℃ of heating in water bath (adding reflux condenser), 60 turn/min stirs 30min, fully dissolving; Place under the room temperature, under the 1500lx daylight lamp, observe Bisolvon dissolving situation respectively at 30min, 60min, 120min, 24h, 48h, 72h, the result is as follows:
The dissolubility (2) of table 5 Bisolvon in glucose solution
+ expression can detect the Bisolvon precipitation
-expression does not detect the Bisolvon precipitation
Previous experiments shows, Bisolvon can be partially dissolved in the glucose injection, illustrates that glucose solution has certain hydrotropy effect to bromhexine hydrochloride, and heated and stirred also can promote its dissolving; But the bromhexine hydrochloride after the dissolving can be separated out from solution again, shows that its stability of solution is poor.
Embodiment 3 supersound process stability study in the Bisolvon glucose solution
Precision takes by weighing Bisolvon sample 3g, adds 5% glucose injection 1000ml, and 30～40 ℃ of supersound process (25kHz, 100w) 50min dissolves fully.Place under the room temperature, under the 1500lx daylight lamp, observe Bisolvon dissolving situation respectively at 30min, 60min, 120min, 24h, 48h, 72h, the result is as follows:
The stability of Bisolvon glucose solution after table 6 supersound process
+ expression can detect the Bisolvon precipitation
-expression does not detect the Bisolvon precipitation
This group is tested and is shown, supersound process can make the Bisolvon glucose solution have no Precipitation more than 72 hours, illustrates that supersound process has stronger Stabilization to the bromhexine hydrochloride glucose solution.
The preparation of embodiment 4 Bisolvon injection of the present invention
Get glucose for injection 5000g and add water for injection 25000ml stirring and dissolving, add the 25g active carbon, boiled 30 minutes, filtering decarbonization gets glucose solution.After letting cool, inject and be diluted with water to 100000ml, stir evenly;
Add Bisolvon 16g, 30～40 ℃ of supersound process (60kHz) 50min makes the dissolving of hydrochloric acid bromocaproic acid, add the 400g active carbon, continue to stir 10 minutes, filter, with sodium hydroxide adjust pH to 4.0～4.5, measure content and related substances, qualified rear mistake 0.45 μ m microporous filter membrane namely gets the Bisolvon glucose injection after the fill.
The preparation of embodiment 5 Bisolvon injection of the present invention
Get glucose for injection 5000g and add water for injection 25000ml stirring and dissolving, add the 50g active carbon, boiled 30 minutes, filtering decarbonization gets glucose solution.After letting cool, inject and be diluted with water to 100000ml, stir evenly;
Add Bisolvon 8g, 30～40 ℃ of supersound process (60kHz) 50min makes the dissolving of hydrochloric acid bromocaproic acid, add the 100g active carbon, continue to stir 10 minutes, filter, with sodium hydroxide adjust pH to 4.0～4.5, measure content and related substances, qualified rear mistake 0.45 μ m microporous filter membrane namely gets the Bisolvon glucose injection after the fill.
The preparation of embodiment 6 Bisolvon injection of the present invention
Get glucose for injection 5000g and add water for injection 25000ml stirring and dissolving, add the 50g active carbon, boiled 30 minutes, filtering decarbonization gets glucose solution.After letting cool, inject and be diluted with water to 100000ml, stir evenly;
Add Bisolvon 4g, 30～40 ℃ of supersound process (60kHz) 50min makes the dissolving of hydrochloric acid bromocaproic acid, add the 150g active carbon, continue to stir 10 minutes, filter, with sodium hydroxide adjust pH to 4.0～4.5, measure content and related substances, qualified rear mistake 0.45 μ m microporous filter membrane namely gets the Bisolvon glucose injection after the fill.
The stability study of embodiment 7 Bisolvon injection of the present invention
According to the requirement of Chinese Pharmacopoeia two appendix XI XC medicine stability test guiding principles in 2010, investigate 40 ℃ of acceleration 6 months and 12 months stability of long-term stable experiment of the Bisolvon glucose injection of embodiment 4 to 6 preparations, the result is as follows:
1, accelerated test
The Bisolvon glucose injection under the listing packing, is placed in the calorstat, and temperature is 40 ± 2 ℃, under relative humidity 75 ± 5% conditions, places six months.Result of the test sees Table 7.
Table 7 Bisolvon glucose injection accelerated test result of the test
2, room temperature keeps sample and investigates test
The Bisolvon glucose injection under the listing packing, in 25 ℃ ± 2 ℃ of temperature, is placed under relative humidity 60% ± 10% condition for a long time.Timing sampling detects, and result of the test sees Table 8.
Table 8 Bisolvon glucose injection long-term test results
Simulation listing packing three batch samples of the present invention preparation were tested 6 months under 40 ℃, RH75% condition, keep sample in room temperature and to have investigated 12 months, experimental result shows, this three batch sample has good stability, the indexs such as its appearance luster, acidity, Clarity and colour of solution, visible foreign matters, related substance, content are without significant change, and are all up to specification.
Claims (8)
1. Bisolvon injection, it is characterized in that, the hydrochloric bromhexine of described Bisolvon infusion pump and glucose, and do not comprise ethanol, the concentration of glucose is 50g/L in the wherein said Bisolvon injection, the concentration of Bisolvon is 0.04g/L ~ 0.16g/L, and the preparation method of described Bisolvon injection comprises: then the isotonic aqueous solution of preparation glucose is dissolved in Bisolvon in the described isotonic aqueous solution by supersound process.
2. the preparation method of Bisolvon injection according to claim 1 is characterized in that, described preparation method comprises: then the isotonic aqueous solution of preparation glucose is dissolved in Bisolvon in the described isotonic aqueous solution by supersound process.
3. preparation method according to claim 2 is characterized in that, described preparation method may further comprise the steps:
1) glucose is soluble in water, filter after then adding activated carbon adsorption, filtrate water is diluted to isotonic concentration, thereby obtains the isotonic aqueous solution of glucose;
2) in the isotonic aqueous solution that obtains through step 1), add Bisolvon, ultrasonicly make hydrochloric acid bromocaproic acid dissolving, filter after then adding activated carbon adsorption, regulate pH value, filtering with microporous membrane.
4. preparation method according to claim 3 is characterized in that, the water in the described step 1) is water for injection.
5. each described preparation method in 4 according to claim 2 is characterized in that, described method comprises:
1) the 5000g glucose for injection is dissolved in the 25L water for injection, adds active carbon 25 to 50g, boil the rear filtering decarbonization of absorption in 30 minutes, then filtrate is diluted to 100L with water for injection, thereby obtains the isotonic aqueous solution of glucose;
2) in the isotonic aqueous solution that obtains through step 1), add 4g ~ 16g Bisolvon, made the dissolving of hydrochloric acid bromocaproic acid in ultrasonic 50 minutes for 30 ~ 40 ℃ lower 25 to 60kHz, then add 100g to 400g active carbon, filter after stirring absorption in 10 minutes, regulate pH value to 4.0 ~ 4.5,0.45 μ m filtering with microporous membrane, packing, sterilization.
6. preparation method according to claim 5 is characterized in that, described step 2) in made hydrochloric acid bromocaproic acid dissolving in ultrasonic 50 minutes at 30 ~ 40 ℃ of lower 60kHz.
7. preparation method according to claim 5 is characterized in that, described step 2) the middle 150g active carbon that adds.
8. Bisolvon injection according to claim 1 is in the purposes of preparation in the expectorant.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110246847 CN102293741B (en) | 2011-08-24 | 2011-08-24 | Bromhexine hydrochlorie injection, its preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110246847 CN102293741B (en) | 2011-08-24 | 2011-08-24 | Bromhexine hydrochlorie injection, its preparation method and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102293741A CN102293741A (en) | 2011-12-28 |
| CN102293741B true CN102293741B (en) | 2013-02-20 |
Family
ID=45354582
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110246847 Active CN102293741B (en) | 2011-08-24 | 2011-08-24 | Bromhexine hydrochlorie injection, its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102293741B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103976945B8 (en) * | 2014-06-04 | 2016-12-21 | 回音必集团(江西)东亚制药有限公司 | A kind of Bisolvon glucose injection |
| CN104434786B (en) * | 2014-12-09 | 2017-04-12 | 河北仁合益康药业有限公司 | Stable bromhexine hydrochloride sodium chloride injection composition |
| CN105534889B (en) * | 2016-01-07 | 2018-11-02 | 河北仁合益康药业有限公司 | A kind of sucking bromhexine hydrochloride liquid composite and preparation method thereof |
| CN111714477B (en) * | 2020-07-23 | 2021-06-15 | 山东迅达康兽药有限公司 | Phlegm eliminating composition and preparation method of oral liquid thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH085784B2 (en) * | 1987-06-17 | 1996-01-24 | 興和株式会社 | Syrup |
| EP1465646A1 (en) * | 2001-12-13 | 2004-10-13 | Council of Scientific and Industrial Research | Bioavailability enhancing activity of zingiber officinale linn and its extracts/fractions thereof |
| CN1184963C (en) * | 2002-09-10 | 2005-01-19 | 张嵩 | Bromhexine hydrochloride injection and its preparation method |
| CN1259041C (en) * | 2004-02-05 | 2006-06-14 | 马小歧 | Bromhexine Hydrochloride aseptic freeze-drying formulation for injection and its preparation method |
| DE102004023930A1 (en) * | 2004-05-12 | 2005-12-08 | Boehringer Ingelheim Vetmedica Gmbh | Fast-dissolving granules of bromhexine / bromhexine hydrochloride, process for its preparation and its use |
| CN1634589A (en) * | 2004-10-04 | 2005-07-06 | 杨喜鸿 | Injection using invert sugar water solution as carrier |
| CN100409835C (en) * | 2007-04-06 | 2008-08-13 | 张嵩 | Composition and great volume injection containing bromhexine salt and the injection preparing process |
-
2011
- 2011-08-24 CN CN 201110246847 patent/CN102293741B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN102293741A (en) | 2011-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102008727B (en) | Injection-purpose medicine composition for improving stability of ligustrazine medicine injection formulation | |
| CN102293741B (en) | Bromhexine hydrochlorie injection, its preparation method and application | |
| CN105106110A (en) | Injectable medicine composition capable of improving stability of puerarin medicine injection preparation and preparation method of injectable medicine composition | |
| CN109432123B (en) | Compound electrolyte glucose injection and preparation method thereof | |
| CN107412152B (en) | Dexmedetomidine hydrochloride injection composition | |
| CN102579329B (en) | Milrinone lactate injection and preparation method thereof | |
| CN103989630A (en) | Moxifloxacin hydrochloride sodium chloride injection and preparation method thereof | |
| CN101190214B (en) | Paclitaxel injection and preparation method thereof | |
| CN1759832A (en) | Carbazochrome sodium sulfonate for injection, and preparation method | |
| CN104706655B (en) | Meglumine cyclic adenosine for injecta powder-injection pharmaceutical composition and preparation method | |
| CN106361983A (en) | Capsule for realizing adjuvant treatment on diabetes and preparation method of capsule | |
| CN107019675A (en) | Adenosine cyclophosphate for injection freeze drying powder injection pharmaceutical composition and quality control method and preparation method | |
| CN102166185A (en) | Isotonic naloxone injection and preparation method thereof | |
| CN102600210B (en) | A kind of compound DM Cough agent and preparation method thereof | |
| CN100998585A (en) | Injection containing meclofenoxate hydrochloride and its preparing method | |
| CN104721223B (en) | A kind of injection pharmaceutical composition of compound electrolyte and preparation method thereof | |
| CN103393593B (en) | Pharmaceutical composition containing ambroxol hydrochloride and fructose | |
| CN104173343B (en) | Milrinone compound and pharmaceutical composition containing milrinone compound | |
| CN110898005B (en) | Toxicity-reducing and synergistic vinorelbine injection and application thereof in resisting lung cancer | |
| CN103432089A (en) | Metformin hydrochloride chewable tablet and preparation method thereof | |
| CN102727427A (en) | Isotonic naloxone injection and preparation method thereof | |
| CN106389315A (en) | Injection pharmaceutical composition for improving stability of sharpleaf galangal fruit drug injection preparation | |
| CN101152204A (en) | Vein drug administration preparations of clofarabine and method for preparing the same | |
| CN100563664C (en) | A kind of liquid preparation and its production and use | |
| CN103479605B (en) | Dilutable ibuprofen pharmaceutical composition and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Zhang Kai Inventor after: Du Yumin Inventor after: Xue Na Inventor after: Han Fengnian Inventor after: Ma Xuwei Inventor before: Zhang Kai Inventor before: Du Yumin Inventor before: Xue Na Inventor before: Han Fengnian Inventor before: Ma Xuwei |
|
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20111228 Assignee: Shijiazhuang Sinopharm Co., Ltd. Assignor: Shijiazhuang Dongfang Pharmaceutical Co., Ltd. Contract record no.: 2014130000104 Denomination of invention: Bromhexine hydrochlorie injection, its preparation method and application Granted publication date: 20130220 License type: Common License Record date: 20140625 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20151225 Address after: Hebei province Shijiazhuang City Xinshi road 050000 No. 375 Patentee after: Shijiazhuang Hankang Biology Chemistry Medicine Co., Ltd. Address before: 050017 No. 17 battalion Avenue, Shijiazhuang, Hebei Patentee before: Shijiazhuang Dongfang Pharmaceutical Co., Ltd. |
|
| CI01 | Correction of invention patent gazette |
Correction item: Assignee of record for patent exploitation license contracts Correct: Shijiazhuang No.4 Pharmaceutical Co., Ltd. False: Shijiazhuang Sinopharm Co., Ltd. Number: 35 Volume: 30 |
|
| ERR | Gazette correction | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20111228 Assignee: Shijiazhuang No.4 Pharmaceutical Co., Ltd. Assignor: Shijiazhuang Hankang Biology Chemistry Medicine Co., Ltd. Contract record no.: 2018130000012 Denomination of invention: Bromhexine hydrochlorie injection, its preparation method and application Granted publication date: 20130220 License type: Common License Record date: 20190104 |
|
| EE01 | Entry into force of recordation of patent licensing contract |